PMID- 28575208
OWN - NLM
STAT- MEDLINE
DCOM- 20190702
LR  - 20221207
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 65
IP  - 7
DP  - 2017 Oct 1
TI  - High Rate of Treatment Completion in Program Settings With 12-Dose Weekly 
      Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
PG  - 1085-1093
LID - 10.1093/cid/cix505 [doi]
AB  - BACKGROUND: Randomized controlled trials have demonstrated that the newest latent 
      tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and 
      rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater 
      completion rate (82% vs 69%); however, 3HP has not been assessed in routine 
      healthcare settings. METHODS: Observational cohort of LTBI patients receiving 3HP 
      through 16 US programs was used to assess treatment completion, adverse drug 
      reactions, and factors associated with treatment discontinuation. RESULTS: Of 
      3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. 
      Children aged 2-17 years had the highest completion rate (94.5% [155/164]). 
      Patients reporting homelessness had a completion rate of 81.2% (147/181). In 
      univariable analyses, discontinuation was lowest among children (relative risk 
      [RR], 0.44 [95% confidence interval CI, .23-.85]; P = .014), and highest in 
      persons aged >/=65 years (RR, 1.72 [95% CI, 1.25-2.35]; P < .001). In multivariable 
      analyses, discontinuation was lowest among contacts of patients with tuberculosis 
      (TB) disease (adjusted RR [ARR], 0.68 [95% CI, .52-.89]; P = .005) and students 
      (ARR, 0.45 [95% CI, .21-.98]; P = .044), and highest with incarceration (ARR, 
      1.43 [95% CI, 1.08-1.89]; P = .013) and homelessness (ARR, 1.72 [95% CI, 
      1.25-2.39]; P = .001). Adverse drug reactions were reported by 1174 (35.7%) 
      patients, of whom 891 (76.0%) completed treatment. CONCLUSIONS: Completion of 3HP 
      in routine healthcare settings was greater overall than rates reported from 
      clinical trials, and greater than historically observed using other regimens 
      among reportedly nonadherent populations. Widespread use of 3HP for LTBI 
      treatment could accelerate elimination of TB disease in the United States.
FAU - Sandul, Amy L
AU  - Sandul AL
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Nwana, Nwabunie
AU  - Nwana N
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Holcombe, J Mike
AU  - Holcombe JM
AD  - Mississippi State Department of Health, Jackson.
FAU - Lobato, Mark N
AU  - Lobato MN
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
AD  - Connecticut Department of Public Health, Hartford.
FAU - Marks, Suzanne
AU  - Marks S
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Webb, Risa
AU  - Webb R
AD  - Mississippi State Department of Health, Jackson.
AD  - University of Mississippi Medical Center, Jackson.
FAU - Wang, Shu-Hua
AU  - Wang SH
AD  - Ohio State University Medical Center, Columbus.
FAU - Stewart, Brock
AU  - Stewart B
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Griffin, Phil
AU  - Griffin P
AD  - Kansas Department of Health and Environment, Topeka.
FAU - Hunt, Garrett
AU  - Hunt G
AD  - Nationwide Children's Hospital, Columbus, Ohio.
FAU - Shah, Neha
AU  - Shah N
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
AD  - California Department of Public Health, San Francisco ; and.
FAU - Marco, Asween
AU  - Marco A
AD  - Arkansas Department of Health, Little Rock.
FAU - Patil, Naveen
AU  - Patil N
AD  - Arkansas Department of Health, Little Rock.
FAU - Mukasa, Leonard
AU  - Mukasa L
AD  - Arkansas Department of Health, Little Rock.
FAU - Moro, Ruth N
AU  - Moro RN
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Jereb, John
AU  - Jereb J
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Mase, Sundari
AU  - Mase S
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Chorba, Terence
AU  - Chorba T
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Bamrah-Morris, Sapna
AU  - Bamrah-Morris S
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
FAU - Ho, Christine S
AU  - Ho CS
AD  - Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral 
      Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 
      Atlanta, Georgia.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Antibiotics, Antitubercular)
RN  - 0 (Antitubercular Agents)
RN  - V83O1VOZ8L (Isoniazid)
RN  - VJT6J7R4TR (Rifampin)
RN  - XJM390A33U (rifapentine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibiotics, Antitubercular/adverse effects/*therapeutic use
MH  - Antitubercular Agents/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination/adverse effects/methods
MH  - Drug-Related Side Effects and Adverse Reactions/etiology
MH  - Female
MH  - Ill-Housed Persons
MH  - Humans
MH  - Isoniazid/adverse effects/*therapeutic use
MH  - Latent Tuberculosis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Mycobacterium tuberculosis/*drug effects
MH  - Rifampin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Students
MH  - United States
MH  - Young Adult
PMC - PMC5709238
MID - NIHMS880952
COIS- Conflicts of Interest: None of the authors have any indirect or direct potential 
      conflicts of interest to disclose.
EDAT- 2017/06/03 06:00
MHDA- 2019/07/03 06:00
PMCR- 2018/10/01
CRDT- 2017/06/03 06:00
PHST- 2017/02/22 00:00 [received]
PHST- 2017/05/26 00:00 [accepted]
PHST- 2017/06/03 06:00 [pubmed]
PHST- 2019/07/03 06:00 [medline]
PHST- 2017/06/03 06:00 [entrez]
PHST- 2018/10/01 00:00 [pmc-release]
AID - 3858897 [pii]
AID - 10.1093/cid/cix505 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2017 Oct 1;65(7):1085-1093. doi: 10.1093/cid/cix505.